双FP/EP3受体激动剂介导小鼠眼压降低过程中FP/EP3受体的作用
研究探讨了双FP/EP3受体激动剂sepetaprost(SPT)在野生型、FP受体缺陷和EP3受体缺陷C57BL/6小鼠中的降眼压效果及房水流出易度变化。SPT降眼压作用持续8小时,长于拉坦前列素;SPT在FPKO和EP3KO小鼠中降眼压作用均减弱,且SPT在野生型小鼠中显著增加房水流出易度,但在FPKO和EP3KO小鼠中增加较少。作者认为SPT降眼压作用更持久可能归因于FP和EP3受体介导的房水流出易度增加。
要点
- SPT在野生型小鼠给药后8小时内显著降低眼压,作用持续时间长于拉坦前列素。
- 给药后2小时,拉坦前列素在WT、FPKO、EP3KO小鼠的降眼压分别为15.3±2.5%、1.8±2.0%、12.3±2.4%;SPT分别为13.6±2.1%、5.9±2.7%、6.6±2.6%。
- SPT在野生型小鼠中显著增加房水流出易度,但在FPKO和EP3KO小鼠中增加较少。
核心结论
- SPT的降眼压作用持续时间长于拉坦前列素,数据提示这可能归因于FP和EP3受体介导的房水流出易度增加。
研究设计与样本
- 在C57BL/6野生型(WT)小鼠、FP受体缺陷(FPKO)小鼠和EP3受体缺陷(EP3KO)小鼠中开展的研究。
- 使用微针测量眼压,采用两级恒压灌注法测量房水流出易度。
主要发现
- SPT在WT小鼠给药后8小时内显著降低眼压。
- 给药后2小时降眼压幅度:拉坦前列素在WT、FPKO、EP3KO小鼠分别为15.3±2.5%、1.8±2.0%、12.3±2.4%;SPT分别为13.6±2.1%、5.9±2.7%、6.6±2.6%。
- 拉坦前列素介导的降眼压在FPKO小鼠中显著减弱,SPT介导的降眼压在FPKO和EP3KO小鼠中均减弱。
- 给药后6小时,拉坦前列素在任一 tested 小鼠品系中均未显著降低眼压;SPT介导的降眼压在FPKO和EP3KO小鼠中均减弱。
- 给药后6小时,同时给予选择性FP和EP3受体激动剂后降眼压显著更高,但单独给予选择性EP3受体激动剂时眼压未下降。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We investigated the intraocular pressure (IOP)-lowering effect of topical sepetaprost (SPT), a dual agonist of the FP and EP3 receptors. We explored whether certain receptors mediated the hypotensive effect of SPT and outflow facility changes in C57BL/6 mice (wild-type [WT]) and FP and EP3 receptor-deficient mice (FPKO and EP3KO mice, respectively). METHODS: IOP was measured using a microneedle. Outflow facility was measured using a two-level, constant-pressure perfusion method. RESULTS: SPT significantly reduced IOP for 8 hours after administration to WT mice. The 2-hour IOP reductions afforded by latanoprost were 15.3 ± 2.5, 1.8 ± 2.0, and 12.3 ± 2.4% in WT, FPKO, and EP3KO mice, respectively; the SPT figures were 13.6 ± 2.1, 5.9 ± 2.7, and 6.6 ± 2.6%, respectively. Latanoprost-mediated IOP reduction was significantly decreased in FPKO mice, and SPT-mediated IOP reduction was reduced in both FPKO and EP3KO mice. At 6 hours after administration, latanoprost did not significantly reduce the IOP in any tested mouse strain. SPT-mediated IOP reduction was reduced in both FPKO and EP3KO mice. IOP reduction at 6 hours was significantly higher after simultaneous administration of selective FP and EP3 receptor agonists, but IOP did not fall on administration of (only) a selective EP3 receptor agonist. SPT significantly increased outflow facility in WT mice, but less so in FPKO and EP3KO mice. CONCLUSIONS: The IOP-lowering effect of SPT lasted longer than that of latanoprost. Our data imply that this may be attributable to augmented outflow facility mediated by the FP and EP3 receptors.
引用
- Yamagishi-Kimura R, Honjo M, Aihara M, et al. The Roles Played by FP/EP3 Receptors During Pressure-lowering in Mouse Eyes Mediated by a Dual FP/EP3 Receptor Agonist. Invest Ophthalmol Vis Sci. 2022. PMID: 35147658. doi:10.1167/iovs.63.2.24
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。